Following FDA clearance, Wandercraft presents Atalante X, the self-stabilizing, hands free, multi-directional gait walking exoskeleton at APTA 2023, the American Physical Therapy Association conference.
New York City, New York Feb 20, 2023 (Issuewire.com) - Wandercraft, a leading manufacturer of healthcare exoskeletons, announced today that it will commercially launch its Atalante rehabilitation walk exoskeleton at the American Physical Therapy Association conference taking place February 23rd-25th in San Diego, CA.
"Wandercraft is delighted to launch Atalante in the USA at the APTA Conference, which gathers our future users. This is a key milestone in Wandercraft's life" said the CEO of Wandercraft, Matthieu Masselin. "For many years, we have shared our development roadmap with many leading rehabilitation hospital teams in the USA. Following their advice and feedback, Wandercraft's team has designed a unique technology to improve rehabilitation care. Atalante is highly successful in Europe, and we believe it will thrive in the innovation-prone USA market.'
Atalante was CE-marked in 2019 and cleared in December 2022 by the U.S. Food and Drug Administration (FDA) in the stroke indication. Every year, more than 795,000 people in the United States have a stroke, a leading cause of serious long-term disability. It has already been used to treat thousands of patients with various medical conditions across multiple European rehabilitation hospitals.
Atalante is designed to enable hands-free, early, intensive, and task-oriented walk and balance rehabilitation treatments. It is initially used for post-stroke patients. Its unique self-balancing feature enables patients to move in multiple directions hands-free, without an assistive device, and includes a dynamic balance mode unavailable elsewhere in the exoskeleton market.
Media contacts
Wandercraft Inc
Gary Viles
VP of commercial operations Americas
+1(813) 435-0772
Media Contact
Wandercraft
+1(813) 435-0772
Source :wandercraft inc
This article was originally published by IssueWire. Read the original article here.
